ArticleJournal of diabetes investigation2018
Early second trimester maternal serum markers in the prediction of gestational diabetes mellitus.
Article in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05846191 (Evaluation of Serum Pentraxin 3 and High Sensitive CRP in Female Patients With Gestational Diabetes Mellitus in Second Trimester of Pregnancy.), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Serum Pentraxin 3 and High Sensitive CRP in Female Patients With Gestational Diabetes Mellitus in Second Trimester of Pregnancy.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- High-mobility group box 1 at the time of parturition in women with gestational diabetes mellitus.American journal of reproductive immunology (New York, N.Y. : 1989) · 2019Trial
- Opportunistic screening data for early prediction of GDM in Northern Chinese women: a multicenter machine learning study.Scientific reports · 2026Article
- Predictive Value of Placental Growth Factor and Soluble FMS-Like Tyrosine Kinase-1 Detection in Early Pregnancy for Gestational Diabetes Mellitus: A Case-Control Study.International journal of women's health · 2026Article
- Association of the GLM7 composite metabolic index with gestational diabetes mellitus in early pregnancy: a secondary analysis of a Korean prospective pregnancy cohort.Frontiers in nutrition · 2026Article
- Diagnostic Utility of Extracellular Levels of Serum Amyloid P and Proteoglycan 4: A Case-Control Study in Gestational Diabetes Mellitus.International journal of general medicine · 2026Article
- Advances in gestational diabetes mellitus screening: Emerging trends and future directions.World journal of diabetes · 2025Review
- Pentraxin-3 as a Biomarker in Diabetes Mellitus: Insights into Inflammation, Vascular Complications, and Modulation by Antidiabetic Medications.Biomedicines · 2025Review
- The role of placental hormones and metabolites in modulating uterine circulation in physiological and pathological pregnancies.Frontiers in endocrinology · 2025Review
- Prediction of gestational diabetes mellitus using early-pregnancy data: a secondary analysis from a prospective cohort study in Iran.BMC pregnancy and childbirth · 2024Article
- Advancement in predictive biomarkers for gestational diabetes mellitus diagnosis and related outcomes: a scoping review.BMJ open · 2024Article
- Predictive Utility of Biochemical Markers for the Diagnosis and Prognosis of Gestational Diabetes Mellitus.International journal of molecular sciences · 2024Review
- Role of Nutritional Habits during Pregnancy in the Developing of Gestational Diabetes: A Single-Center Observational Clinical Study.Medicina (Kaunas, Lithuania) · 2024Article
- Evaluating the Adipose Tissue Depth as a Predictor Factor for Gestational Diabetes in Later Pregnancy-A Systematic Review.Biomedicines · 2023Review
- Do Serum Galectin-9 Levels in Women with Gestational Diabetes and Healthy Ones Differ before or after Delivery? A Pilot Study.Biomolecules · 2023Article
- Diagnostic accuracy of first and early second trimester multiple biomarkers for prediction of gestational diabetes mellitus: a multivariate longitudinal approach.BMC pregnancy and childbirth · 2022Article
- Galectins in Early Pregnancy and Pregnancy-Associated Pathologies.International journal of molecular sciences · 2021Review
- Placental secretome characterization identifies candidates for pregnancy complications.Communications biology · 2021Article
- Placental and maternal sFlt1/PlGF expression in gestational diabetes mellitus.Scientific reports · 2021Article
- Gas Chromatography-Mass Spectroscopy-Based Metabolomics Analysis Reveals Potential Biochemical Markers for Diagnosis of Gestational Diabetes Mellitus.Frontiers in pharmacology · 2021Article
- Myostatin as a Biomarker of Muscle Wasting and other Pathologies-State of the Art and Knowledge Gaps.Nutrients · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionTo determine whether maternal serum markers in the early second trimester are useful for prediction of gestational diabetes mellitus (GDM). MATERIALS AND
methodsA total of 876 singleton pregnancies were recruited in the present study. Blood samples were collected during 16-20 gestational weeks. GDM women were diagnosed by an oral glucose tolerance test during 24-28 gestational weeks. A total of 56 women with GDM and 73 healthy pregnant women were selected. Maternal serum concentrations of placental protein 13 (PP13), pentraxin 3 (PTX3), soluble fms-like tyrosine kinase-1 (sFlt-1), myostatin and follistatin (FST) were detected at 16-20 weeks' gestation. All of these markers concentrations were expressed as multiples of the medians. The Mann-Whitney U-test was used for comparison of the multiples of the medians of different concentrations of these five serum markers between the GDM group and the control group. Receiver operating characteristic curve analysis was applied to assess the sensitivity and specificity of significant serum markers from a Mann-Whitney U-test comparison.
resultsCompared with healthy pregnancies, the serum levels of PP13, PTX3, sFlt-1, myostatin and FST in the early second trimester were significantly increased in patients who had developed GDM late. In screening for GDM by PP13, PTX3, sFlt-1, myostatin and FST, the detection rates were 92.3, 94.9, 94.9, 92.5 and 92.3%, respectively at 80% specificity. PTX3 and sFlt-1 were the most sensitive markers.
conclusionsMaternal serum markers including PP13, PTX3, sFlt-1, myostatin and FST increase in the early second trimester of women with GDM. These five markers, especially PTX3 and sFlt-1, could have the value of prediction for those patients who would develop GDM in the late second trimester.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.